Hemispherx announces exclusive revenue sharing agreement with GP Pharm

Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx"), announced that the Company executed an exclusive revenue sharing Sales, Marketing, Distribution and Supply Agreement for Argentina with GP Pharm Latinoamerica ("GP Pharm"), an affiliate company of Spanish GP Pharm SA (www.gp-pharm.com). Under this Agreement, GP Pharm will be responsible for gaining regulatory approval in Argentina for Ampligen®, an experimental therapeutic, to treat Chronic Fatigue Syndrome ("CFS") in Argentina and for commercializing Ampligen® for this indication in Argentina. The Company has granted GP Pharm the right to expand rights to sell this experimental therapeutic into other Latin America countries based upon GP Pharm achieving certain performance milestones. The Company has also granted GP Pharm an option to market Alferon N Injection®, its FDA approved natural interferon, in Argentina and other Latin America countries as well. Under this Agreement, the Company will manufacture and supply Ampligen® to GP Pharm.

Thomas Kenwood Equels, recently appointed Executive Vice Chairman of Hemispherx and the leader of its world-wide marketing efforts, stated, "I am very pleased to have Hemispherx working with GP Pharm SA and their affiliates. Its Latin American Director, Jorge Braver, is a very experienced and effective pharmaceutical executive in Argentina and elsewhere in Latin America. I believe this relationship will eventually lead to opening large markets for Hemispherx's platform technologies in Latin America."

Mr. Braver of GP Pharm said, "Thousands of people suffer from ME/CFS (Myalgic Encephalomyelitis / Chronic Fatigue Syndrome), a particularly insidious disease for which there is no known cure, in Argentina and elsewhere in Latin America. We are looking forward to expanding our relationship with Hemispherx by undertaking the commercialization of Ampligen® in Latin America. We are also excited to have the opportunity to market the FDA approved product, Alferon N Injection®, a natural interferon with a proven track record of safety and historically demonstrated exceptional anti-viral capabilities, throughout Latin America."